TOKYO -- Japanese drugmaker Daiichi Sankyo is racing to develop Japan's own messenger RNA vaccine, aiming for release by the end of next year, as CEO Sunao Manabe looks beyond COVID to make the technology a pillar of the company's future business.
"We are directing all available resources" to the development of the COVID vaccine, Manabe said in an interview with Nikkei Asia. "We are hurrying. We want to make the vaccine available to people as early as possible."
